摘要
全身麻醉后苏醒期躁动(EA)可发生意外伤害等严重的并发症,右美托咪定作为一种高选择性α2肾上腺素能受体激动剂,可用于气管内插管重症患者的镇静和围术期麻醉的辅助用药,有研究证实右美托咪定可用于减少全身麻醉术后苏醒期躁动的发生率,本文就目前右美托咪定用于苏醒期躁动治疗的研究进展进行综述,为临床降低EA的发生提供参考。
Emergence agitation(EA) after general anesthesia may result in serious complications such as accidental injury, Dexmedetomidine is a highly selective alpha 2 adrenergic agonist. It can be used for sedation and perioperative anesthesia in severe endotracheal intubation patients, some studies have shown that it can reduce the incidence of emergence agitation after general anesthesia. In this review, the current research progress of dexmedetomidine in the treatment of emergence agitation were reviewed to provide a reference for the clinical reduction of EA.
作者
姜晶晶
鲁卫华
JIANG Jing-jing(Department of Critical Care Medicine,Yijishan Hospital,Wannan Medical College,Wuhu,Anhui,241000,China)
出处
《齐齐哈尔医学院学报》
2020年第18期2313-2315,共3页
Journal of Qiqihar Medical University
基金
安徽省中央引导地方科技发展专项项目(201907d07050001)
皖医弋矶山医院“高峰”培育计划(GF2019J03)
安徽省科技计划公益性技术应用研究联动计划(1604f0804043)
安徽省学术和技术带头人后备人选科研活动经费资助项目(2017H145)。
关键词
全身麻醉
苏醒期躁动
右美托咪定
Generalanesthesia
Emergence agitation
Dexmedetomidine
